Department of Health Sciences, University of Leicester, Leicester, UK.
Division of Respiratory Medicine, University of Nottingham, Nottingham, UK; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK; Nottingham Molecular Pathology Node, University of Nottingham, Nottingham, UK.
Lancet Respir Med. 2017 Nov;5(11):869-880. doi: 10.1016/S2213-2600(17)30387-9. Epub 2017 Oct 20.
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high mortality, uncertain cause, and few treatment options. Studies have identified a significant genetic risk associated with the development of IPF; however, mechanisms by which genetic risk factors promote IPF remain unclear. We aimed to identify genetic variants associated with IPF susceptibility and provide mechanistic insight using gene and protein expression analyses.
We used a two-stage approach: a genome-wide association study in patients with IPF of European ancestry recruited from nine different centres in the UK and controls selected from UK Biobank (stage 1) matched for age, sex, and smoking status; and a follow-up of associated genetic variants in independent datasets of patients with IPF and controls from two independent US samples from the Chicago consortium and the Colorado consortium (stage 2). We investigated the effect of novel signals on gene expression in large transcriptomic and genomic data resources, and examined expression using lung tissue samples from patients with IPF and controls.
602 patients with IPF and 3366 controls were selected for stage 1. For stage 2, 2158 patients with IPF and 5195 controls were selected. We identified a novel genome-wide significant signal of association with IPF susceptibility near A-kinase anchoring protein 13 (AKAP13; rs62025270, odds ratio [OR] 1·27 [95% CI 1·18-1·37], p=1·32 × 10) and confirmed previously reported signals, including in mucin 5B (MUC5B; rs35705950, OR 2·89 [2·56-3·26], p=1·12 × 10) and desmoplakin (DSP; rs2076295, OR 1·44 [1·35-1·54], p=7·81 × 10). For rs62025270, the allele A associated with increased susceptibility to IPF was also associated with increased expression of AKAP13 mRNA in lung tissue from patients who had lung resection procedures (n=1111). We showed that AKAP13 is expressed in the alveolar epithelium and lymphoid follicles from patients with IPF, and AKAP13 mRNA expression was 1·42-times higher in lung tissue from patients with IPF (n=46) than that in lung tissue from controls (n=51).
AKAP13 is a Rho guanine nucleotide exchange factor regulating activation of RhoA, which is known to be involved in profibrotic signalling pathways. The identification of AKAP13 as a susceptibility gene for IPF increases the prospect of successfully targeting RhoA pathway inhibitors in patients with IPF.
UK Medical Research Council, National Heart, Lung, and Blood Institute of the US National Institutes of Health, Agencia Canaria de Investigación, Innovación y Sociedad de la Información, Spain, UK National Institute for Health Research, and the British Lung Foundation.
特发性肺纤维化(IPF)是一种具有高死亡率、病因不明和治疗选择有限的慢性进行性肺部疾病。研究已经确定了与 IPF 发展相关的重要遗传风险;然而,遗传风险因素促进 IPF 的机制仍不清楚。我们旨在确定与 IPF 易感性相关的遗传变异,并通过基因和蛋白质表达分析提供机制见解。
我们使用了两阶段方法:在英国九个不同中心招募的欧洲血统的 IPF 患者和从英国生物银行选择的年龄、性别和吸烟状况匹配的对照进行全基因组关联研究(第 1 阶段);并在来自芝加哥联盟和科罗拉多联盟的两个独立的美国样本的 IPF 患者和对照的独立数据集(第 2 阶段)中对相关遗传变异进行了随访。我们研究了新型信号对大型转录组和基因组数据资源中基因表达的影响,并使用来自 IPF 患者和对照的肺组织样本进行了表达研究。
第 1 阶段选择了 602 名 IPF 患者和 3366 名对照。第 2 阶段选择了 2158 名 IPF 患者和 5195 名对照。我们在 A-激酶锚定蛋白 13(AKAP13;rs62025270,优势比[OR]1·27[95%CI 1·18-1·37],p=1·32 × 10)附近发现了一个与 IPF 易感性相关的新全基因组显著信号,并证实了先前报道的信号,包括粘蛋白 5B(MUC5B;rs35705950,OR 2·89[2·56-3·26],p=1·12 × 10)和桥粒芯蛋白(DSP;rs2076295,OR 1·44[1·35-1·54],p=7·81 × 10)。对于 rs62025270,与增加 IPF 易感性相关的等位基因 A 也与肺切除术患者肺组织中 AKAP13 mRNA 的表达增加相关(n=1111)。我们表明 AKAP13 在来自 IPF 患者的肺泡上皮细胞和淋巴滤泡中表达,并且来自 IPF 患者的肺组织中的 AKAP13 mRNA 表达比对照(n=51)高 1.42 倍(n=46)。
AKAP13 是一种 Rho 鸟苷酸交换因子,调节 RhoA 的激活,已知 RhoA 参与致纤维蛋白信号通路。将 AKAP13 确定为 IPF 的易感基因增加了在 IPF 患者中成功靶向 RhoA 途径抑制剂的前景。
英国医学研究理事会、美国国立卫生研究院国家心肺血液研究所、西班牙加那利群岛研究、创新和信息社会局、英国国家卫生研究院和英国肺脏基金会。